Skip to main content
Premium Trial:

Request an Annual Quote

Nuevolution, CRT Partner in Cancer Compound Hunt

NEW YORK (GenomeWeb News) – The Danish drug discovery firm Nuevolution said today that it will collaborate with Cancer Research Technology, the commercial branch of Cancer Research UK, to identify possible drug candidates for use in cancer treatments.

Under the collaboration, Nuevolution will use its Chemetics technology, which uses DNA labeling for small-molecule drug screening, to identify drug leads that block the activity of a number of cancer targets, the company said.

CRT will harness CRUK's cancer research network to provide biological information about the targets on which the partners plan to focus their efforts. CRT also will provide expertise in in vitro screening assays, cellular activity assays, and other drug discovery activities.

Any further pre-clinical development of promising small molecules the partners identify will be worked out under a separate agreement between Nuevolution and CRT, the company said.

Hamish Ryder, CRT's director of drug discovery for its Discovery Laboratories, said in a statement that the collaboration "will allow us to address a number of 'low-tractability' cancer targets" that have made cancer drug discovery difficult, and will enable them to assess hundreds of millions of potential compounds.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.